GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy Via SIRT1 Pathway

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2023 Aug 21

PMID 37602204

Authors

Jie Xiang

Liyan Qin

Jinling Zhong

Ning Xia

Yuzhen Liang

Affiliations

Soon will be listed here.

Abstract

Background: Obesity is related to the loss of skeletal muscle mass and function (sarcopenia). The co-existence of obesity and sarcopenia is called sarcopenic obesity (SO). Glucagon like peptide-1 receptor agonists (GLP-1RA) are widely used in the treatment of diabetes and obesity. However, the protective effects of GLP-1RA on skeletal muscle in obesity and SO are not clear. This study investigated the effects of GLP-1RA liraglutide and semaglutide on obesity-induced muscle atrophy and explored the underlying mechanisms.

Methods: Thirty-six male C57BL/6J mice were randomly divided into two groups and fed a regular diet and a high-fat diet for 18 weeks, respectively. After establishing an obesity model, mice were further divided into six groups: control group, liraglutide (LIRA) group, semaglutide (SEMA) group, high-fat diet (HFD) group, HFD + LIRA group, HFD + SEMA group, and subcutaneous injection for 4 weeks. The body weight, muscle mass, muscle strength, glycolipid metabolism, muscle atrophy markers, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed. C2C12 myotube cells treated with palmitic acid (PA) were divided into four groups: control group, PA group, PA + LIRA group, PA + SEMA group. The changes in glucose uptake, myotube diameter, lipid droplet infiltration, markers of muscle atrophy, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed, and the changes in related indicators were observed after the addition of SIRT1 inhibitor EX527.

Results: Liraglutide and semaglutide reduced HFD-induced body weight gain, excessive lipid accumulation and improved muscle atrophy. Liraglutide and semaglutide eliminated the increase of muscle atrophy markers in skeletal muscle and C2C12 myotubes. Liraglutide and semaglutide restored impaired glucose tolerance and insulin resistance. However, these beneficial effects were attenuated by inhibiting SIRT1 expression.

Conclusion: Liraglutide and semaglutide protects skeletal muscle against obesity-induced muscle atrophy via the SIRT1 pathway.

Citing Articles

Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis.

Cheah M, Crane H, George J Hepatol Int. 2025; .

PMID: 40087205 DOI: 10.1007/s12072-025-10801-x.

The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Regulates Sirtuin-1-Mediated Neutrophil Extracellular Traps to Improve Diabetes-Induced Bone Metabolism Imbalance.

Zhong S, Huang L, Lin T, Li Y, Deng B, Kong D Iran J Pharm Res. 2025; 23(1):e148139.

PMID: 40066121 PMC: 11892751. DOI: 10.5812/ijpr-148139.

Spotlight on the Mechanism of Action of Semaglutide.

Papakonstantinou I, Tsioufis K, Katsi V Curr Issues Mol Biol. 2024; 46(12):14514-14541.

PMID: 39728000 PMC: 11674233. DOI: 10.3390/cimb46120872.

Deciphering the mechanisms and effects of hyperglycemia on skeletal muscle atrophy.

Gaur K, Mohapatra L, Wal P, Parveen A, Kumar S, Gupta V Metabol Open. 2024; 24:100332.

PMID: 39634609 PMC: 11616592. DOI: 10.1016/j.metop.2024.100332.

Molecular mechanisms of lipid droplets-mitochondria coupling in obesity and metabolic syndrome: insights and pharmacological implications.

Zhang C, Zheng M, Bai R, Chen J, Yang H, Luo G Front Physiol. 2024; 15:1491815.

PMID: 39588271 PMC: 11586377. DOI: 10.3389/fphys.2024.1491815.

References

Zhang X, Xie X, Dou Q, Liu C, Zhang W, Yang Y . Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: a updated meta-analysis. BMC Geriatr. 2019; 19(1):183. PMC: 6610788. DOI: 10.1186/s12877-019-1195-y. View

Nemoto S, Fergusson M, Finkel T . SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem. 2005; 280(16):16456-60. DOI: 10.1074/jbc.M501485200. View

Boozer C, SCHOENBACH G, Atkinson R . Dietary fat and adiposity: a dose-response relationship in adult male rats fed isocalorically. Am J Physiol. 1995; 268(4 Pt 1):E546-50. DOI: 10.1152/ajpendo.1995.268.4.E546. View

Secher A, Jelsing J, Baquero A, Hecksher-Sorensen J, Cowley M, Dalboge L . The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014; 124(10):4473-88. PMC: 4215190. DOI: 10.1172/JCI75276. View

Milne J, Denu J . The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol. 2008; 12(1):11-7. DOI: 10.1016/j.cbpa.2008.01.019. View

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A . Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117(3):399-412. PMC: 3619734. DOI: 10.1016/s0092-8674(04)00400-3. View

Yang M, Liu S, Zhang C . The Related Metabolic Diseases and Treatments of Obesity. Healthcare (Basel). 2022; 10(9). PMC: 9498506. DOI: 10.3390/healthcare10091616. View

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T . Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19(9):1242-1251. PMC: 5573908. DOI: 10.1111/dom.12932. View

You B, Dun Y, Fu S, Qi D, Zhang W, Liu Y . The Treatment of Rhodiola Mimics Exercise to Resist High-Fat Diet-Induced Muscle Dysfunction via Sirtuin1-Dependent Mechanisms. Front Pharmacol. 2021; 12:646489. PMC: 8082455. DOI: 10.3389/fphar.2021.646489. View

10.

Donini L, Busetto L, Bischoff S, Cederholm T, Ballesteros-Pomar M, Batsis J . Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022; 15(3):321-335. PMC: 9210010. DOI: 10.1159/000521241. View

11.

Maliszewska K, Adamska-Patruno E, Kretowski A . The interplay between muscle mass decline, obesity, and type 2 diabetes. Pol Arch Intern Med. 2019; 129(11):809-816. DOI: 10.20452/pamw.15025. View

12.

Pahor M, Manini T, Cesari M . Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging. 2009; 13(8):724-8. PMC: 4312657. DOI: 10.1007/s12603-009-0204-9. View

13.

Sishi B, Loos B, Ellis B, Smith W, Du Toit E, Engelbrecht A . Diet-induced obesity alters signalling pathways and induces atrophy and apoptosis in skeletal muscle in a prediabetic rat model. Exp Physiol. 2010; 96(2):179-93. DOI: 10.1113/expphysiol.2010.054189. View

14.

Rafael J, Nitta Y, Peters J, Davies K . Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. Mamm Genome. 2000; 11(9):725-8. DOI: 10.1007/s003350010149. View

15.

Listenberger L, Han X, Lewis S, Cases S, Farese Jr R, Ory D . Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A. 2003; 100(6):3077-82. PMC: 152249. DOI: 10.1073/pnas.0630588100. View

16.

Fujita H, Shimizu K, Nagamori E . Novel method for fabrication of skeletal muscle construct from the C2C12 myoblast cell line using serum-free medium AIM-V. Biotechnol Bioeng. 2009; 103(5):1034-41. DOI: 10.1002/bit.22318. View

17.

Schiaffino S, Dyar K, Ciciliot S, Blaauw B, Sandri M . Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013; 280(17):4294-314. DOI: 10.1111/febs.12253. View

18.

Andrikopoulos S, Blair A, Deluca N, Fam B, Proietto J . Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008; 295(6):E1323-32. DOI: 10.1152/ajpendo.90617.2008. View

19.

Lauterbach M, Wunderlich F . Macrophage function in obesity-induced inflammation and insulin resistance. Pflugers Arch. 2017; 469(3-4):385-396. PMC: 5362664. DOI: 10.1007/s00424-017-1955-5. View

20.

Rothwell N, Stock M . The development of obesity in animals: the role of dietary factors. Clin Endocrinol Metab. 1984; 13(3):437-49. DOI: 10.1016/s0300-595x(84)80032-8. View